Quick Answer
Vaxcyte, Inc. reported Stockholders Equity of $2.69 billion for the year ending 2025.
- Vaxcyte, Inc. showed a decrease of -18.8% in Stockholders Equity from 2024 to 2025.
- This data is from Vaxcyte, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: -$71.11 million | Q2 2019: -$81.48 million | Q3 2019: -$92.16 million | Q1 2020: -$132.97 million | Q2 2020: $383.21 million | Q3 2020: $364.08 million | Q1 2021: $326.94 million | Q2 2021: $317.03 million | Q3 2021: $305.96 million | Q1 2022: $359.54 million | Q2 2022: $366.50 million | Q3 2022: $359.31 million | Q1 2023: $944.77 million | Q2 2023: $1.43 billion | Q3 2023: $1.40 billion | Q1 2024: $1.98 billion | Q2 2024: $1.99 billion | Q3 2024: $3.42 billion | Q1 2025: $3.20 billion | Q2 2025: $3.07 billion | Q3 2025: $2.89 billion.
- Over the full 9 years of available data (2017 to 2025), Vaxcyte, Inc.'s Stockholders Equity has grown by 9,319.1%.
- Historical annual values: Fiscal year 2025: $2.69 billion | Fiscal year 2024: $3.31 billion | Fiscal year 2023: $1.24 billion | Fiscal year 2022: $953.61 million | Fiscal year 2021: $284.02 million | Fiscal year 2020: $345.84 million | Fiscal year 2019: -$106.37 million | Fiscal year 2018: -$57.73 million | Fiscal year 2017: -$29.13 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: